Compare AKAM & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKAM | PODD |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 17.0B |
| IPO Year | 1999 | 2007 |
| Metric | AKAM | PODD |
|---|---|---|
| Price | $95.89 | $202.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 20 |
| Target Price | $107.87 | ★ $347.55 |
| AVG Volume (30 Days) | ★ 5.2M | 774.1K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 3.07 | ★ 3.48 |
| Revenue | $2,502,996,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $8.53 | $24.59 |
| Revenue Next Year | $7.09 | $19.18 |
| P/E Ratio | ★ $31.46 | $57.81 |
| Revenue Growth | 6.96 | ★ 30.73 |
| 52 Week Low | $69.79 | $194.61 |
| 52 Week High | $121.12 | $354.88 |
| Indicator | AKAM | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 34.65 |
| Support Level | $95.37 | N/A |
| Resistance Level | $117.60 | $299.75 |
| Average True Range (ATR) | 6.47 | 5.70 |
| MACD | -2.57 | 1.07 |
| Stochastic Oscillator | 24.79 | 45.06 |
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.